Pharma Now

India is often called the "Pharmacy of the World," and for good reason. The country supplies a huge share of the generic medicines used across the globe, and it is also one of the biggest producers of vaccines and active pharmaceutical ingredients, the raw chemical components that go into a finished drug. Behind this reputation is a group of large, well-established Indian pharmaceutical companies that manufacture everything from everyday tablets to complex biosimilars.

RxSight appoints Aziz Mottiwala as President and CEO, succeeding Ron Kurtz in planned leadership transition. Breaking News Jul 18, 2026 Simantini Singh Deo RxSight, Inc. has announced a planned leadership transition that will take effect on July 20, 2026.

Angelini Pharma completes Catalyst Pharmaceuticals acquisition to expand its global brain health business. Breaking News Jul 18, 2026 Simantini Singh Deo Angelini Pharma S.p.A., the international pharmaceutical company and part of Angelini Industries, has completed its acquisition of Catalyst Pharmaceuticals, Inc.

Diagonal Therapeutics doses first patient in Phase 1/2 trial of DIAG723 for hereditary hemorrhagic telangiectasia. Breaking News Jul 18, 2026 Simantini Singh Deo Diagonal Therapeutics, a clinical-stage biotechnology company developing disease-modifying clustering antibodies for severe diseases, has announced that the first patient has been dosed in the DIAMOND Phase 1/2 clinical trial evaluating DIAG723 for the treatment of hereditary hemorrhagic telangiectasia (HHT).

Plus Therapeutics partners with Genomic Testing Cooperative to expand its CNSide precision oncology platform. Breaking News Jul 18, 2026 Simantini Singh Deo Plus Therapeutics, Inc. and Genomic Testing Cooperative (GTC) have announced a strategic collaboration to integrate GTC's next-generation sequencing (NGS) technology into the CNSide® cerebrospinal fluid (CSF) assay platform.

Amneal Pharmaceuticals, Inc. has received approval from the U.S. Food and Drug Administration (FDA) for additional strengths and vial presentations of iohexol injection, further expanding its portfolio of injectable contrast agents. The newly approved products include iohexol injection 350 mg iodine/mL in 50 mL, 75 mL, and 100 mL vials, as well as iohexol injection 300 mg iodine/mL in a 50 mL vial. The company plans to commercially launch these products during the third quarter of 2026.

by Simantini Singh Deo 14 minutes The Top 20 Contract Manufacturing Organizations In The USA, covering pharma, biologics, and medical device CMOs. If you have ever wondered how a medicine or a supplement bottle actually gets made before it reaches a pharmacy shelf, there is a good chance a "CMO" was behind it. CMO stands for Contract Manufacturing Organization. In plain words, it is a company that other companies hire to make their products for them.

Rinascera Therapeutics launches with initial funding to advance treatments for rare genetic skin diseases. Breaking News Jul 17, 2026 Simantini Singh Deo Rinascera Therapeutics, a clinical-stage biotechnology company focused on developing treatments for rare genetic skin diseases, has officially launched after securing its initial financing. The funding round was led by Double Point Ventures, with participation from Olive Tree Capital, Civilization Ventures, and Toba Capital.

Arcutis Biotherapeutics, Inc., a commercial-stage biopharmaceutical company focused on advancing innovative treatments in immuno-dermatology, has announced the appointment of Christopher "Chris" Peetz to its Board of Directors, effective July 15, 2026. The company believes his extensive leadership experience in building and growing biopharmaceutical organizations will support its next phase of expansion.

Clearmind Medicine reports positive ex vivo results for its intranasal MEAI formulation in its Alcohol Use Disorder program. Breaking News Jul 17, 2026 Simantini Singh Deo Clearmind Medicine Inc., a clinical-stage biotechnology company developing non-hallucinogenic neuroplastogen-based therapies for Alcohol Use Disorder (AUD), addiction, and weight management, has announced encouraging results from an ex vivo study evaluating its intranasal formulation of MEAI (5-Methoxy-2-aminoindane).